






27 MAY 2021

~\$5.7m in CY2021 revenue expected from German partner DEMECAN following CYQ4 firm order of \$2.5m

ASX ANNOUNCEMENT

Highlights:

-  Little Green Pharma receives additional \$2.5m firm purchase order from DEMECAN for ~21,300 units (~320kg) of LGP's high THC cannabis flower medicine
-  Purchase order is for delivery during the quarter ended 31 December 2021 and follows consistent growth in size of quarterly DEMECAN purchase orders
-  Annualised run-rate based on DEMECAN CYQ4 purchase order would be ~1,300kgs per annum, exceeding original target of 1,000kgs per annum, equivalent to ~\$10.2m in revenue
-  Reflects the demand from Germany and the confidence in LGP quality and supply
-  LGP production facilities now in full operation. Further production capacity a priority

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce the receipt of an additional firm purchase order for ~21,300 units of the Company's high-THC medicinal cannabis flower medicine from German pharmaceutical wholesaler Deutsche Medizinalcannabis GmbH ("DEMECAN"). The purchase order has a value of \$2.5m and represents ~320kg of flower for delivery during the quarter ending 31 December 2021.

LGP's Managing Director, Fleta Solomon, commented that:

"This order means a lot more than just the value of the sales it represents, it's tangible evidence of the success of our strategy. We are currently in a position where all flower product we produce is sold into Australia and overseas markets and we have customers looking for more. It heightens the urgency for us to focus on increasing our production capacity to capitalize on the brand equity we have built in the market."





This is the fourth purchase order received from DEMECAN, following previous quarterly orders of 500, 9,000, and 17,000 units for delivery in CYQ1, Q2, and Q3 of 2021, respectively. DEMECAN has now ordered a total of ~47,800 units of LGP medicines which would bring the total revenue for CY2021 to ~\$5.7m from DEMECAN alone. The annualised run-rate based on this CYQ4 order would be ~1,300kgs per annum, which would significantly exceed the original target run-rate of 1,000kgs per annum under the medicinal cannabis purchase agreement (refer ASX announcement dated 27 February 2020), and would bring the total annualized DEMECAN revenues to ~\$10.2m per annum.

The Company has brought its existing cultivation facilities to full capacity in order to capitalise on growing demand in the German market, as well as increasing demand from Australian and other offshore markets.

ENDS

Alistair Warren

Company Secretary

Alistair Warren

Company Secretary

Little Green Pharma

E: alistair@lgpharma.com.au

T: +61 8 6280 0050

Fleta Solomon

Managing Director

Little Green Pharma

E: fleta@lgpharma.com.au

T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp